Certified by Founder
Lodge
smartbax
start up
Germany
- München
- 24/05/2023
- Seed
- $1,291,000
smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
- Industry Biotechnology Research
- Website https://www.smartbax.de/
- LinkedIn https://www.linkedin.com/company/smartbax-gmbh/
Project Eleven | $20,000,000 | (Jan 16, 2026)
CYB3R OPERATIONS | $5,400,000 | (Jan 16, 2026)
Quadric | $30,000,000 | (Jan 16, 2026)
GovDash | $30,000,000 | (Jan 16, 2026)
RouteSense | $2,000,000 | (Jan 16, 2026)
Vista AI | $29,500,000 | (Jan 16, 2026)
depthfirst | $40,000,000 | (Jan 16, 2026)
Slips | $3,500,000 | (Jan 16, 2026)
FOVC | $2,000,000 | (Jan 16, 2026)
VoiceRun | $5,500,000 | (Jan 16, 2026)
Emversity | $30,000,000 | (Jan 16, 2026)
Ammobia | $7,500,000 | (Jan 16, 2026)
Pinch AI | $5,000,000 | (Jan 16, 2026)